
Merck's Oral PCSK9 Inhibitor Approval Undercuts Injectables
George Padron
Specialty Medicine, Healthcare Headlines, FDA & Regulations, Cardiology, Access & Affordability, Prior Authorization, Managed Care, Formulary & Coverage, Pharmacy Benefit Trends | Jul 17, 2026
FDA approves Lipfendra (enlicitide), the first oral PCSK9 inhibitor, at $315 a month. Merck priced it under the injectables and moved PCSK9 into retail pharmacy.
Load More